MicroRNA expression profile in head and neck cancer: HOX-cluster embedded microRNA-196a and microRNA-10b dysregulation implicated in cell proliferation by Severino, Patricia  et al.
  Universidade de São Paulo
 
2013
 
MicroRNA expression profile in head and neck
cancer: HOX-cluster embedded microRNA-
196a and microRNA-10b dysregulation
implicated in cell proliferation
 
 
BMC Cancer. 2013 Nov 09;13(1):533
http://www.producao.usp.br/handle/BDPI/43600
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Epidemiologia - FSP/HEP Artigos e Materiais de Revistas Científicas - FSP/HEP
RESEARCH ARTICLE Open Access
MicroRNA expression profile in head and neck
cancer: HOX-cluster embedded microRNA-196a
and microRNA-10b dysregulation implicated in
cell proliferation
Patricia Severino1*, Holger Brüggemann2, Flavia Maziero Andreghetto1, Carme Camps3,
Maria de Fatima Garrido Klingbeil4, Welbert Oliveira de Pereira1, Renata Machado Soares1, Raquel Moyses5,
Victor Wünsch-Filho6, Monica Beatriz Mathor4, Fabio Daumas Nunes7, Jiannis Ragoussis2 and Eloiza Helena Tajara8
Abstract
Background: Current evidence implicates aberrant microRNA expression patterns in human malignancies;
measurement of microRNA expression may have diagnostic and prognostic applications. Roles for microRNAs in
head and neck squamous cell carcinomas (HNSCC) are largely unknown. HNSCC, a smoking-related cancer, is one
of the most common malignancies worldwide but reliable diagnostic and prognostic markers have not been dis-
covered so far. Some studies have evaluated the potential use of microRNA as biomarkers with clinical application
in HNSCC.
Methods: MicroRNA expression profile of oral squamous cell carcinoma samples was determined by means of DNA
microarrays. We also performed gain-of-function assays for two differentially expressed microRNA using two
squamous cell carcinoma cell lines and normal oral keratinocytes. The effect of the over-expression of these
molecules was evaluated by means of global gene expression profiling and cell proliferation assessment.
Results: Altered microRNA expression was detected for a total of 72 microRNAs. Among these we found well
studied molecules, such as the miR-17-92 cluster, comprising potent oncogenic microRNA, and miR-34, recently
found to interact with p53. HOX-cluster embedded miR-196a/b and miR-10b were up- and down-regulated,
respectively, in tumor samples. Since validated HOX gene targets for these microRNAs are not consistently
deregulated in HNSCC, we performed gain-of-function experiments, in an attempt to outline their possible role. Our
results suggest that both molecules interfere in cell proliferation through distinct processes, possibly targeting a small
set of genes involved in cell cycle progression.
Conclusions: Functional data on miRNAs in HNSCC is still scarce. Our data corroborate current literature and
brings new insights into the role of microRNAs in HNSCC. We also show that miR-196a and miR-10b, not previously
associated with HNSCC, may play an oncogenic role in this disease through the deregulation of cell proliferation. The
study of microRNA alterations in HNSCC is an essential step to the mechanistic understanding of tumor formation and
could lead to the discovery of clinically relevant biomarkers.
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Background
MicroRNAs (miRNAs) are ~22 nt non-coding RNA
molecules that negatively regulate gene expression by
degrading or destabilizing the messenger RNA (mRNA)
or by inhibiting protein translation [1]; some reports
demonstrate that they may also function as positive reg-
ulators [2,3]. MiRNAs have been shown to contribute to
cancer development and progression, and are differen-
tially expressed between normal tissues and cancers [4].
Although the function of most of the miRNAs identified
to date has yet to be determined, their use as potential
biomarkers or therapeutic targets has been considered in
several human diseases and cancers [5,6].
Head and neck squamous cell carcinoma (HNSCC) is a
significant public health entity, representing the sixth lead-
ing cancer by incidence worldwide [7,8]. Genetic changes
that bring about HNSCC are usually a consequence of
continued exposure to carcinogens associated with to-
bacco. Despite advances in medical and surgical treatment,
the overall 5-year survival rate for patients with HNSCC
remains around 50% [8]. A recent work by Liu et al., 2009
[9] analyzed data compiled by the American Cancer Soci-
ety and points out that new cases of HNSCC increased
25% during the past 5 years, highlighting the need for a
better understanding of the molecular events leading to
the development of this disease.
The number of studies addressing the contribution of
miRNA deregulation in the context of HNSCC is, how-
ever, limited [10,11]. Some of these studies have evalu-
ated the potential use of miRNAs as biomarkers with
clinical application, associating the expression levels of
some of these miRNAs with survival rates or metastatic
potential [12-16]. Overall, results are promising, but still
preliminary and lacking corroboration.
In our study we determined the miRNA expression
profile of oral squamous cell carcinoma (OSCC) sam-
ples, a type of cancer that represents 90% of all HNSCC
[9]. We also performed functional assays for two differ-
entially expressed miRNAs, miR-196 and miR-10b, since
neither have been previously associated with HNSCC.
Despite studies linking these miRNAs to the regulation
of homeobox (HOX) genes [17,18] our data suggest that,
in the case of HNSCC, they have little impact in HOX
gene expression. We demonstrate that miR-10b and
miR-196a interfere in cell proliferation through distinct
processes and in a cell-type dependent manner.
Methods
Samples
Fifteen patients with OSCC (tongue and floor of the
mouth) were selected for the microarray experiments. In
order to validate the microarray results, 35 additional
patients with HNSCC (oral cavity, oropharynx and lar-
ynx) were selected. The clinical and pathological profile
of patients is shown in Table 1. The average age of pa-
tients was 55.5 years (SD 9.8, range 38–82 years), and
the male/female ratio was 24:1. Most patients were
smokers or former smokers and had a history of chronic
alcohol abuse. Tumor and corresponding cancer free
surgical margins containing the corresponding epithe-
lium were collected from patients submitted to surgical
resection of primary tumor at Hospital das Clinicas,
Hospital Heliopolis and Arnaldo Vieira de Carvalho
Cancer Institute, in Sao Paulo, Brazil. All patients pro-
vided written informed consent, and the research proto-
col was approved by review boards of all institutions
involved and by the National Committee of Ethics in Re-
search (CONEP 1763/05). Samples corresponding to the
oral cavity, base of the tongue and larynx were snap-
frozen in liquid nitrogen immediately after surgery and
stored in liquid nitrogen until RNA preparation. Frozen
samples were sectioned using a cryostat, and tissue sec-
tions were stained with RNAse-free reagents. Analysis of
hematoxylin and eosin-stained sections by the study pa-
thologists confirmed >75% tumor cells in all HNSCC
samples and that surgical margins were tumor-free. The
diagnosis of HNSCC was confirmed, and tumors were
histologically examined for perineural invasion (tumor
cells in the perineural space or epineurium), tumor dif-
ferentiation (well, moderated or poorly differentiated, ac-
cording to the WHO guidelines), lymphatic-vascular
invasion, surgical margins, and lymph node metastasis.
Tumors were staged according to the TNM clinical sta-
ging system, as proposed by the International Union
Against Cancer.
RNA isolation
Total RNA was prepared from tissue using mirVana
miRNA Isolation Kit (Ambion, Austin, TX) in compli-
ance with the manufacturer’s protocol. RNA integrity
and concentration were assessed using the RNA 6000
Nano Assay kit with Agilent 2100 Bioanalyzer according
to the manufacturer’s instructions (Agilent Technolo-
gies, Palo Alto, CA).
miRNA microarray expression profiling
MiRNA expression profiling was performed using the
Illumina miRNA arrays version 1.0. Sample preparation
and hybridization followed the manufacturer’s instruc-
tions. Briefly, 200 ng of total RNA was first polyadeny-
lated and converted to biotinylated cDNA, which was
attached to a solid phase and hybridised with a pool of
miRNA-specific oligonucleotides (MSO). Each single
MSO is used to assay one miRNA on the panel. Univer-
sal PCR amplification was then performed, creating fluo-
rescently labeled products identifiable by their unique
MSO sequence. These products were hybridized on the
Illumina miRNA array, with the address sequence from
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Table 1 Clinical and pathological data of patients in this study
Patient Site Gender Age (yr) Pathologic stage Histological differentiation
1 OC-FOM Male 72 T2N0M0 Moderate
2 OC-T Male 55 T3N0M0 Moderate
3 OC-FOM Male 75 T2N0M0 Moderate
4 OC-FOM Male 46 T1N2bM0 Well
5 OC-T Male 66 T3N0M0 Moderate
6 OC-T Male 59 T2N2cM0 Well
7 OC-T Male 49 T4aN2bM0 Well
8 OC-FOM Male 53 T4aN1M0 Moderate
9 OC-T Female 82 T1N0M0 Well
10 OC-FOM Male 69 T4aN2cM0 Moderate
11 OC-T Male 52 T3N2cM0 Moderate
12 OC-FOM Male 59 T4aN2bM0 Moderate
13 OC-FOM Male 56 T4aN3M0 Moderate
14 OC-FOM Male 51 T2N0M0 Moderate
15 OC-FOM Male 54 T4aN2bM0 Well
16 OC-T Male 55 T2N0M0 Moderate
17 OC-T Male 43 T3N0M0 Moderate
18 OP-BOT Male 47 T4aN0M0 Well
19 OC-FOM Male 64 T4aN2cM0 Moderate
20 OC-T Male 57 T4aN2bM0 Moderate
21 OC-FOM Male 67 T3N0M0 Well
22 L Male 64 T3N0M0 Moderate
23 OC-FOM Male 44 T2N2bM0 Well
24 OC-FOM Male 63 T3N2cM0 Moderate
25 OC-FOM Male 40 T4aN0M0 Moderate
26 OC-FOM Male 45 T4aN2cM0 Well
27 OC-FOM Male 51 T4aN1M0 Moderate
28 OC-FOM Male 56 T4aN0M0 Well
29 L Male 68 T2N0M0 Well
30 OC-FOM Male 63 T3N0M0 Moderate
31 OC-FOM Male 46 T4aN3M0 Well
32 OC-FOM Male 68 T4aN1M0 Well
33 OC-FOM Male 40 T4aN2cM0 Moderate
34 OC-FOM Male 61 T2N2bM0 Moderate
35 OP-BOT Male 41 T3N0M0 Moderate
36 OC-FOM Male 62 T3N0M0 Moderate
37 OP-BOT Male 55 T2N3M0 Moderate
38 OP-BOT Male 51 T3N3M0 Moderate
39 OC-FOM Female 46 T2N0M0 Well
40 OP-BOT Male 48 T2N2cM0 Moderate
OC-T, oral cavity – tongue; OC-FOM, oral cavity - floor of mouth; OP-BOT, oropharynx – Base of tongue; L, larynx. Patients 1–15 were used for microRNA gene
expression profiling by means of microarray analysis.
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each MSO enabling the hybridization of specific miRNA
products to specific locations on the BeadArray sub-
strate. Hybridization signals were detected and quanti-
fied using Illumina scanner and BeadStudio version
3.2.7. Average signals were quantile normalized and then
filtered according their detection p-value: only miRNAs
for which the detection p-value was consistently equal
or lower than 0.05 across at least one group of samples
(marginal and/or tumor samples) were considered
expressed and further analyzed. All data is MIAME
compliant and the raw data has been deposited in a
MIAME compliant database (Gene Expression Omnibus
database) under accession Number GSE31277. Differen-
tially expressed miRNAs were determined by using the
Rank Product, non-parametric statistical method based
on ranks of fold-changes [19]. We used the RankProd
package on R for this analysis; the percentage of false
positives was calculated and p-values were accordingly
corrected for multiple comparisons.
Relative quantification of miRNA levels using real time-PCR
To validate the microarray expression data, miRNAs were
subjected to quantitative Real Time-PCR using the TaqMan
miRNA assay system (Applied Biosystems, Foster City,
CA). Briefly, about 100 ng of total RNA was subjected to a
reverse transcription reaction using miRNA-specific looped
primers according to the manufacturer’s protocol to obtain
the cDNA. Subsequent PCRs used miRNA specific forward
and reverse primers along with appropriate cDNA product
and TaqMan universal mix. PCR was carried out in
AB7500 (Applied Biosystems, Foster City, CA) in a 20 ul
volume reaction following thermal cycling parameters sug-
gested by the manufacturer: 50°C for 2 min, 95°C for 10
min and 45 cycles of 95°C for 15 s and 60°C for 1 min.
The expression data was normalized to the RNU48 ex-
pression. RNU48 was chosen as a suitable endogenous
control gene following analysis of gene expression stabil-
ity of three candidate genes across our samples. For a
detailed description of this step refer to the next
Methods’ section. Expression levels were determined
using the comparative ΔCt method [20].
For miRNAs individually studied in independent sets of
samples by quantitative real-time PCR, the nonparametric
test Wilcoxon Signed Rank Test was used to detect the
statistically significant differences between paired normal
tissue (N) and tumor (T) samples obtained from the same
individual. This test was performed using SPSS for Win-
dows® Software. The same software was used to calculate
the mean and standard deviation of all variables.
Identification of suitable endogenous control gene for
microRNA gene expression analysis by real-time PCR
The expression of three snoRNAs (RNU6B, RNU44 and
RNU48) was measured by quantitative real-time PCR
with TaqMan miRNA assays (Applied Biosystems, Foster
City, CA), as previously described for all samples assayed
by miRNA microarrays. This data was analyzed using the
SLqPCR package in R [21] to determine the expression
stability of these snoRNAs across samples. The stability
factor M was calculated for each snoRNA (M (for
RNU48) = 0.69; M (for RNU44) = 0.78; M (for RNU6B) =
0.75). Since high expression stability is associated to low
M values, RNU48 appeared to be the snoRNA with most
stable expression across the set of samples analyzed, hence
was chosen as control for normalisation.
Prediction of miRNA targets and their functional analysis
Potential miRNA targets were identified using Ingenuity
Pathway Analysis (IPA Ingenuity Systems, www.ingenuity.
com). Only experimentally validated targets were selected,
using miRecords (http://mirecords.biolead.org/), Tarbase
(http://microrna.gr/tarbase) or TargetScan (http://www.
targetscan.org/). For fuctional annotation of potential tar-
gets we used KEGG pathways term enrichment analysis
using the computational tool Database for Annotation,
Visualization and Integrated Discovery (DAVID) v6.7
(http://david.abcc.ncifcrf.gov/home.jsp).
HNSCC cell line and keratinocyte cell culture
The HNSCC cell lines SCC25 and SCC9, derived from a
SCC of the tongue, and FaDu, derived from a SCC of the
hypopharynx were used in this study. They were obtained
from American Type Culture Collection (SCC25 catalog
number CRL-1628, SCC9 catalog number CRL-1629, and
FaDu catalog number HTB-43). The cell lines were grown
in a Dulbecco’s Modified Eagle’s medium/Nutrient Mix-
ture F-12 Ham (DMEM/F12) supplemented with 10% fetal
bovine serum in a humidified atmosphere of 5% CO2 and
95% air at 37°C. Oral keratinocytes were obtained from
primary cultures of the buccal mucosa, from voluntary
donor patients undergoing surgery performed in out-
patient clinics in the Dentistry School of USP. The pa-
tients were informed and signed the required Informed
Consent. This study was approved by the Research Ethics
Committee of the Instituto de Pesquisas Energéticas e
Nucleares (IPEN/CNEN-SP) [Institute of Energy and Nu-
clear Research] (approval number 087/CEP-IPEN/SP).
Keratinocytes were plated on a support layer, called
feeder-layer, composed of murine fibroblasts of the type
3T3-Swiss albino (ATCC, catalog number CCL-92), which
were irradiated (60 Gy), and maintained in an incubator at
37°C, in a humidified atmosphere containing 5% CO2 and
grown as previously described [22].
Transfection of cultured cells for up-regulation of miRNAs
The siPORT NeoFx reagent (Ambion) was used for
transfection following the manufacturer’s protocol. For
up-regulation, the Ambion Pre-miR™ miRNA Precursor
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Molecule (hsa-miR-10b and hsa-miR-196a) was used,
with Ambion’s Pre-miR negative control #1. Successful
up-regulation was achieved with 50 nM of final Pre-miR
miRNA Precursor concentration.
Immunofluorescence assay for proliferation analysis
Normal keratinocytes transfected with the miRNA precur-
sor and the negative control were cultured in Lab-Tek
Chamber Slides (Nalge Nunc International, Rochester, NY,
Table 2 Deregulated miRNAs between 15 OSCC and 15 tumor-free surgical margins
miRNA Fold-change P value miRNA Fold-change P value
hsa-miR-196a 7.94 0 hsa-miR-1 −6.67 0
hsa-miR-33 5.51 0 hsa-miR-30a-3p −3.34 0
hsa-miR-19a 3.29 0 hsa-miR-139 −3.13 0
hsa-miR-33b 2.65 0 hsa-miR-133a −3.79 0
hsa-miR-142-5p 2.81 0 hsa-miR-486 −3.02 0
hsa-miR-503 2.53 0 hsa-miR-135a −3.47 0
hsa-miR-31 2.40 0 hsa-miR-204 −2.68 0
hsa-miR-7 2.33 0 hsa-miR-206 −3.42 0
hsa-miR-19b 2.66 0 hsa-miR-411 −2.67 0
hsa-miR-135b 2.29 0 hsa-miR-499 −2.64 0
hsa-miR-632 2.15 0 hsa-miR-10b −2.39 0
hsa-miR-504 1.99 0 hsa-miR-99a −2.35 0
hsa-miR-187 2.10 0 hsa-miR-299-5p −2.46 0
hsa-miR-339 2.12 1.00E-04 hsa-miR-379 −2.42 0
hsa-miR-302d 1.93 1.00E-04 hsa-miR-100 −2.17 0
hsa-miR-34b 2.06 1.00E-04 hsa-miR-30a-5p −2.13 0
hsa-miR-34c 2.02 2.00E-04 hsa-miR-95 −2.16 1.00E-04
hsa-miR-455 2.06 3.00E-04 hsa-miR-378 −2.08 1.00E-04
hsa-miR-9 1.99 3.00E-04 hsa-miR-218 −1.88 1.00E-04
hsa-miR-296 1.93 3.00E-04 hsa-miR-368 −2.00 2.00E-04
hsa-miR-301 2.02 3.00E-04 hsa-miR-363 −1.83 2.00E-04
hsa-miR-130b 1.97 3.00E-04 hsa-miR-128a −1.90 4.00E-04
hsa-miR-196b 1.93 4.00E-04 hsa-miR-655 −1.94 6.00E-04
hsa-miR-200a 1.96 4.00E-04 hsa-miR-376a −1.83 1.00E-03
hsa-miR-210 1.87 7.00E-04 hsa-miR-628 −1.87 1.00E-03
hsa-miR-17-3p 1.87 9.00E-04 hsa-miR-487b −1.95 1.00E-03
hsa-miR-302b* 1.76 9.00E-04 hsa-miR-410 −1.81 1.00E-03
hsa-miR-224 1.59 9.00E-04 hsa-miR-140 −1.79 2.00E-03
hsa-miR-183 1.78 9.00E-04 hsa-miR-801 −1.34 2.00E-03
hsa-miR-138 1.79 1.00E-03 hsa-miR-376a* −1.80 2.00E-03
hsa-miR-188 1.63 2.00E-03 hsa-miR-154 −1.76 3.00E-03
hsa-miR-92b 1.66 2.00E-03 hsa-miR-432 −1.80 3.00E-03
hsa-miR-182 1.66 2.00E-03 hsa-miR-328 −1.64 3.00E-03
hsa-miR-144 1.42 3.00E-03
hsa-miR-146b 1.42 4.00E-03
hsa-miR-182* 1.61 4.00E-03
hsa-miR-149 1.53 4.00E-03
hsa-miR-141 1.67 4.00E-03
hsa-miR-610 1.34 5.00E-03
Negative Fold-Change indicates over-expression in margins. p-values indicate the significance level for each gene and have been multiple-test-corrected using
Rank Products as described in Methods. *: identifies the star strand of a miRNA.
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USA) for the immunofluorescence assay. Cells were fixed
with methanol, blocked with 3% bovine serum in PBS, and
incubated for 1 h with antihuman Ki67 (Monoclonal
Mouse, clone MIB-1, DAKO, Denmark A/5), diluted
1:400. Cells were washed with PBS and incubated at room
temperature for 45 minutes with secondary antibody con-
jugated with fluorescein (1:50) (Novocastra Laboratories,
UK), in a dark chamber. Following washing, chambers
containing the cells were mounted with VECTASHIELD
Mounting Medium with DAPI (Vector Laboratories,
Ind. Buelingame, CA 94010). Results were analyzed by
fluorescence microscopy (Zeiss Axiophot II, Carl Zeiss,
Oberköchen, Germany). The percentage of cells display-
ing Ki67 labeling was determined by counting the num-
ber of positive Ki67 stained cells as a proportion of the
total number of cells counted. Cells were counted
manually in the whole chamber area.
Proliferation assay by flow cytometry
Cell lines SCC9, SCC25 and FaDu were stained with Cell
Trace Violet (Molecular Probes®), according to the
manufacturer protocol. Briefly, the cells were incubated
with 5 μM Cell Trace Violet for 20 minutes at 37°C,
washed twice with fresh and warmed medium and cul-
tured under regular conditions. The cells were run on
BD LSR Fortessa flow cytometer with 405 nm laser at
day zero and after 72 hours of cell culture for cell prolif-
eration rate assessment. Proliferation rate was deter-
mined by fluorescence decay. Analysis was performed
using Flow Jo software (Tree Star™). For cell proliferation
rates after transfection, cell lines SCC25 and FaDu were
stained 24 h after transfection (at the time of medium
exchange). Proliferation rates were compared between
scramble (negative control) and cells overexpressing
miR-10b.
Figure 1 MiR-196 and MiR-10b are deregulated in HNSCC as measured by relative qRT-PCR. A: MiR-196a, miR-10b expression in thirty-nine
paired tissue samples (fold-change between cancer and adjacent normal mucosa) of primary HNSCC. B: MiR-196b expression in forty paired tissue
samples (fold-change between cancer and adjacent normal mucosa) of primary HNSCC. C: MiR-10b expression in forty paired tissue samples
(fold-change between cancer and adjacent normal mucosa) of primary HNSCC. Wilcoxon Signed Rank Test was used to evaluate the difference in
gene expression levels between cancer and normal tissue and a statistically significant difference was found between cancer and cancer-free tis-
sue for the expression levels of the three tested miRNAs (p < 0.05).
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mRNA microarray expression profiling and analysis
Following the transfection assays, the global gene expres-
sion analysis was conducted using the Agilent Human
Whole Genome Oligonucleotide Microarray (44K; Agilent
Technologies) following the manufacturer’s protocols.
Oligonucleotide microarrays were scanned using the Gen-
ePix 4000B Microarray Scanner (Molecular Devices) and
features were automatically extracted and analyzed for
quality control using Agilent Feature Extraction Software.
Raw data was deposited in a MIAME compliant database
(Gene Expression Omnibus database) under the accession
Number GSE31277. Partek Genomics Suite 6.6 (Partek In-
corporated) was used for normalization of gene expression
levels and for fold-change in gene expression calculation.
To gain insights into the potential mechanisms affected by
the overexpression of the miR-10b and miR-196a in cells,
deregulated genes were mapped to regulatory networks
using Ingenuity Pathway Analysis (IPA Ingenuity Systems,
www.ingenuity.com).
Western blotting
Western blotting was performed using a specific anti-
body against annexin 1 (1:1000 dilution) (Zymed La-
boratories - 713400), and β-Actin (1:12.000 dilution)
(Cell Signaling Technology, Danvers, MA, USA). Briefly,
72 hours after transfection cells were lysed in RIPA
buffer (150 mM NaCl, 10 mM Tris/HCl, pH 7.4, 0.5%
Triton X-100 and protease and phosphatase inhibitors
(Biogene). Protein concentration was estimated using
the BCA Protein Assay Kit (BioAgency, London, UK).
20 ug of protein lysate was separated in 15% SDS gel
(GE Healthcare, Piscataway, NJ, USA) and subsequently
transferred to nitrocellulose membrane of 0,45 μm (GE
Healthcare, Piscataway, NJ, USA). The membranes were
blocked using 3% non-fat dry milk, and incubated with
primary antibodies overnight at 4°C. The membranes were
washed in 1x TBS eith 0.1% Tween-20 (TBS/T), incubated
for 1 h with anti-rabbit secondary antibodies conjugated
FaDu day 3 
FaDu day 0 
SCC25 day 3 
SCC25 day 0 SCC9 day 0 
SCC9 day 3 
Cell Trace Violet 
SS
C 
Figure 2 Proliferation rate of SCC9, SCC25 and FaDu cell lines as determined by flow cytometry. Proliferation rate was determined by
fluorescence decay from measures at day 0 to day 3 (72 h). Numerical results are presented in Table 3.
Table 3 Assessment of the number of cell divisions after
72h of cell culture
Initial Final MFI Predicted # cell divisions
FaDu 109,219.96 6,826.24 3-4
SCC25 102,353.5 6,397.08 3-4
SCC9 152,640.3 19,080.0 2-3
Prediction of the number of cell divisions according to formula final MFI =
initial MFI/2n. MFI, mean fluorescence index; n, number of cell divisions. final
MFI = initial MFI/2n.
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to horseradish peroxidase (Abcam - ab102779) and visua-
lized with a chemiluminescence reagent (ECL) system
(Amersham Biosciences, Arlington Heights, IL).
Results and discussion
MiRNA deregulation in OSCC samples: implication in
tumor progression
HNSCC can involve multiple anatomical sites, each with
individual molecular characteristics, and highly affected by
the drinking and smoking habits of patients [13,23,24]. In
an attempt to limit data variability due to HNSCC subsites
and environmental factors, we assessed miRNA expression
levels in 15 OSCC samples limited to tongue and floor of
the mouth, from patients possessing similar demographic
and clinico-pathological characteristics (Table 1, detailed
in Methods). Samples were paired with tumor-free
surgical margins. The expression profiles of tumor sam-
ples revealed significant differential expression for 72 miR-
NAs compared to their corresponding tumor-free margins
(Table 2). Several studies have analysed the miRNA ex-
pression profile of OSCC cell lines and tumor samples,
with little overlap among results [25,26]. This inconsist-
ency in results justifies additional studies.
In order to access biological processes possibly targeted
by deregulated miRNAs we performed a functional analysis
of validated targets through KEGG term enrichment ana-
lysis using the computational tool DAVID. Thirty-eight of
the 72 deregulated miRNAs possessed mRNA targets that
have been experimentally observed; in total 609 genes are
potentially regulated (Additional file 1). These genes were
mapped to KEGG pathways and were shown to be broadly
involved in cancer development (Additional file 2).
Figure 3 Expression of miR-10b in the cell lines SCC25, SCC9 and FaDu, and of miR-196a in normal keratinocytes following transfection
with the specific miRNA precursor molecules. A: Expression of miR-10b in the cell lines SCC25, SCC9 and FaDu following transfection with the
specific miRNA precursor molecule; B: Expression of of miR-196a in normal keratinocytes following transfection with the specific miRNA precursor
molecule. Scramble represents cells transfected with a random sequence of precursor miRNA molecules validated by the manufacturer to not
produce identifiable effects on known miRNA function. Fold change compares expression levels in transfected and scramble.
Figure 4 Ki67 proliferation marker was detected by immunocytochemistry in keratinocytes. A significantly lower number of Ki67-positive
cells were observed upon over-expression of the miR-196a (*p < 0.05). The bars represent standard deviation and t-test was used for
statistical analysis.
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Figure 5 (See legend on next page.)
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Specifically, members of the miR-17-92 cluster were
deregulated in our dataset: miR-19a and miR-19b were
strongly up-regulated, in addition to moderate up-
regulation of miR-17-3p/miR-17-5p and miR-92b. These
results are in line with the observation that the miR-17-
92 cluster is up-regulated in many cancer types, includ-
ing lung cancer and lymphoma [27,28]. Accordingly,
miR-17-92 cluster members have been shown to take
part in feedback loops determining the role of c-MYC as
tumor suppressor and/or oncogene [29,30]. Specifically,
c-MYC apparently possesses a tumorigenic role in
HNSCC, constituting a current candidate for anticancer
strategies [31]. Recently, the miR-17-92 cluster has been
also shown to regulate multiple components of the
TGF-β pathway in neuroblastoma [32]. Other cancer-
related miRNAs up-regulated in our OSCC samples are
members of the miR-34 family: miR-34b and miR-34c.
To our knowledge this is the first report of their altered
expression profile in HNSCC, although the deregulation
of miR-34a has been recently addressed in HNSCC [33].
These results are interesting in light of the finding that
miR-34 is a direct target of p53, functioning downstream
of the p53 pathway as a tumor suppressor [34,35]. Simi-
lar to other types of cancer, inactivation of p53 is an ex-
tremely common event in head and neck cancers, with
mutant p53 status found in nearly 50% of the cases and
commonly associated with poor prognosis [36]. How-
ever, the role of miR-34b/c in the context of p53 regula-
tion has not been addressed in HNSCC.
In agreement with most miRNA profiles in HNSCC
samples and tumor cell lines, miR-133a was also down-
regulated in our cancer set as compared to tumor-free
samples. Its tumor suppressor activity, for instance by
controlling the target genes actin-related protein 2/3
complex subunit 5 (ARPC5) and moesin (MSN), has
been already demonstrated in squamous cell carcinoma
of the tongue [37-39]. Since this seems to be a robust
characteristic in HNSCC, its function should be further
investigated as well as its possible use as a biomarker for
early cancer detection.
Deregulation of homeobox cluster-encoded miRNAs
miR-196a/b and miR-10b
MiR-196a/b was over-expressed and miR-10b was
down-regulated in the OSCC samples compared with
tumor-free surgical margins (Table 2). Both miRNAs
are dysregulated in a variety of cancers [40,41], but
have not been previously associated with OSCC. We
validated our microarray results in an additional subset
of OSCC samples as well as in samples belonging to
other HNSCC subsites (Figure 1, and Table 1 for sam-
ple characteristics). Both miRNAs clearly presented dif-
ferential expression between tumor and tumor-free
samples, suggesting a role in HNSCC.
MiR-196a/b and miR-10b are embedded within
homeobox (HOX) clusters of developmental regulators
[42]. Schimanski and collaborators [43] demonstrated that
HOX genes are targeted by miR-196, and HOX transcripts
were also experimentally validated as miR-10 targets
[44,45]. Given that molecular events involved in carcino-
genesis interfere in the regulation of cell identity, it has
been proposed that HOX proteins could be oncogenic
regulators [46]. HOX genes have not been implicated in
the development of HNSCC, as judged from reviewing the
available literature, including HNSCC gene expression
profiles. This suggests that the homeobox-cluster embed-
ded miRNA could have a different role in HNSCC. Thus,
we performed gain-of-function experiments aiming to
outline a possible role for these molecules.
Gain-of-function of miR-10b and miR-196a lead to im-
paired cell proliferation
Precursor molecules of miR-10b were transfected into
SCC25 and SCC9 (tongue squamous cell carcinoma-
derived cell lines) and FaDu (a cell line derived from
hypopharyngeal squamous cell carcinoma), while miR-
196a precursor molecules were transfected into human
keratinocytes derived from normal oral epithelium. We
chose SCC cell lines and oral keratinocytes as models
for the investigation of miRNA function in a HNSCC
genetic background, emulating cancer and tumor-free
cellular systems, respectively.
Two SCC cell lines were initially chosen for the gain-
of-function experiments due to differences in their pro-
liferation rates, as reported in Figure 2 and Table 3, a
characteristic that could affect results.
As expected, in untreated SCC cell lines, miR-196 was
up-regulated and miR-10b was downregulated when ex-
pression levels were compared to untreated keratino-
cytes (data not shown).
After transfection, we assessed the over-expresssion of
the respective mature miRNAs in each cell line (Figure 3).
Despite the successful overexpression of miR-10b in
SCC9, these cells were very sensitive to the transfection,
(See figure on previous page.)
Figure 5 miRNA-10b over expression decreases proliferation rate of head and neck cancer cells. Fadu and SCC25 cell lines were
transfected with miR-10b precursor and negative control (scramble) and the proliferation rate was measured for 72 hours. A and C: Zebra plot
showing the fluorescence decay after 72 hours post-transfection with miRNA in Fadu and SCC25 cell lines, respectively. B and D: Graph represent-
ing the percentage of proliferating cells after 72 hours post-transfection with miRNA. The bars represent standard deviation and t-test was used
for statistical analysis. **:p < 0.01. **:p < 0.001.
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with intense effects in cell proliferation seen also for the
negative control. Thus this cell line was not used in subse-
quent experiments.
Since tumor cells evade programmed cell death and sus-
tain proliferative status [47], we tested whether miR-10b
and/or miR-196a could play a role in this scenario. Assess-
ment of Ki-67 antigen expression, a cell proliferation
marker, revealed that keratinocytes over-expressing miR-
196a were mostly quiescent, as defined by a lack of Ki-67
antigen expression. When compared to transfection con-
trols, cell proliferation was reduced approximately 5 fold
in keratinocytes over-expressing miR-196a (Figure 4).
Despite inhibiting cell proliferation, specific occur-
rences at the cell surface level, such as surface blebbing,
considered as a marker for apoptosis, were absent at 72
h after transfection (data not shown). Changes in nuclear
morphology indicating late apoptosis were also absent.
Inhibition of cell proliferation upon over-expression of
miR-10b in SCC25 and FaDu was assessed by flow cy-
tometry (Figure 5). This is consistent with the miRNA
expression data: miR-10b was detected in low levels in
HNSCC in this study, a downregulation that would
thwart the inhibitory effect of miR-10b on cell prolifera-
tion. The effect of the overexpression of miR-10b was
clearly more intense in FaDu as compared to SCC25.
Given the fact that miR-196a was found to be overex-
pressed in HNSCC samples, the inhibitory effect of miR-
196a overexpression on proliferation of normal keratinocyes
cannot easily put into context. One hypothesis could be
that miR-196a overexpression in HNSCC could also be the
Figure 6 Western blot analysis of ANXA1 expression in keratinocytes upon overexpression of miR-196a. Total protein extracts from cells
overexpressing miR-196a (miR-196a) and negative controls (scramble) were analyzed by western blot for ANXA1. Results show no differences in
protein levels between the experiments.
Figure 7 Pathway analysis of deregulated genes upon miR-196a overexpression in keratinocytes. Shown is the most significant
interaction network based on deregulated genes in miR-196a overexpressing keratinocytes, calculated by IPA. The network is termed “DNA repli-
cation, recombination and repair, cell cycle”. In grey, deregulated genes from gene expression profiling.
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consequence of uncontrolled proliferation, as a means to
counteract it, rather than the cause of its perturbation.
Efforts to understand the global effects of miR-196a,
which might be cell-type dependent, are essential con-
sidering that it has been recently addressed as a poten-
tial therapeutic target [41].
Gene expression profiles upon overexpression of miR-10b
and miR-196a do not show regulation of known targets
The identification of miRNA target genes is critical in
order to understand their roles. However, this task is chal-
lenging. MiRNAs are usually imperfectly complementary
to the 3′UTR region of their mRNA targets in mammalian
cells, with target effect hardly detected at the gene expres-
sion level. Additionally, the cellular environment is key in
determining miRNA functions, which will vary depending
on the cell type.
While keeping these drawbacks in mind, global gene ex-
pression profiling using DNA microarrays was performed
in this study to identify deregulated cellular processes
upon the overexpression of miR-10b and miR-196a in
each cell model. Broad consequences of the overexpres-
sion should be detected by global gene expression profil-
ing, even when the deregulation of specific target genes
might not be detected by this kind of experiment.
Experimentally validated mRNA targets were searched
in Tarbase and miRecord databases. None of the miR-
10b targets HOXA1, HOXD10 and KLF4 [40,48,49] were
affected at the mRNA level by the overexpression of
miR-10b in SCC25 or FaDu (Additional files 3 and 4, re-
spectively). The same was true for the miR-196a gene tar-
gets ANXA1, HOXA7, HOXB8, HOXC8, HOXD8, KRT5
and S100A9 [42,50,51] (Additional file 5). These results
suggest that, at least at the mRNA levels these genes are
not targeted by miR-196a in the cells used here.
Figure 8 Pathway analysis of deregulated genes upon miR-10b overexpression in FaDu cell line. Shown is the most significant interaction
network based on deregulated genes in miR-10b overexpressing FaDu cell line, calculated by IPA. The network includes genes involved in the
regulation of cell cycle progression and arrest. In grey, deregulated genes from gene expression profiling.
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Among the above mentioned gene targets, only ANXA1
down-regulation has been previously reported in HNSCC
[52,53]. For this reason, we checked for alterations of this
target also at the protein level. Our results demostrate that
ANXA1 is not targeted by miR-196a under the conditions
studied here (Figure 6).
MiR10b and miR196a lead to cell cycle arrest through
different mechanisms
We performed a functional analysis of deregulated genes
aiming to pinpoint alterations that could explain im-
paired proliferation. A total of 353 annotated genes were
downregulated (at 1.5 fold-change) following miR-196a
over-expression in keratinocytes (Additional file 5). The
relationships among these genes were assessed using In-
genuity Pathway Analysis (IPA), while considering only
experimentally proven connections between genes or pro-
teins. The most significant interaction network consisted
of genes associated with DNA replication, recombination
and repair, cell cycle and, consequently, cancer. Figure 7
depicts this network and genes involved in cell cycle
arrest are highlighted. This network contains 8 deregulated
genes from our dataset: CDK2, SYNM (DMN), TP73,
AKT1, NFATC4, HOXA9, HSPB3 and CD40LG. Of par-
ticular interest is the downregulation of CDK2 and AKT1
and the upregulation of TP73. CDK2 is a subunit of the
cyclin-dependent protein kinase complex, expressed in
G1-S phase, and essential for cell cycle G1/S phase transi-
tion. TP73, up-regulated in cells overexpressing miR-196a,
transcriptionally activates target genes leading to apoptosis
and growth arrest [54]. The activation of PI3K/AKT path-
way in HNSCC is well known; the pathway regulates cell
proliferation and has been addressed as a therapeutical
target. Thus, the expression patterns of these three genes,
following over-expression of miR-196a, would be in
agreement with the observed arrest of the cell cycle.
However, none of them are direct targets of this miRNA
and further studies are needed in order to comprehend
the observed effect.
Overexpression of miR-10b in SCC25 and in FaDu
provided relatively similar results. Two hundred and ten
annotated genes were downregulated and 169 were up-
regulated when SCC25 cells overexpressing miR-10b
were compared to controls (Additional file 3) while 161
genes were downregulated and 169 upregulated in FaDu
overexpressing miR-10b (Additional file 4), when at least
a 2-fold difference was considered. Sixteen common
genes were downregulated in both cell lines, but none of
these genes were miR-10b predicted targets.
Regulatory networks provided by IPA did not contain a
significant number of genes directly implicated in cell pro-
liferation or cell cycle arrest for SCC25 cell line. This ana-
lysis, however, highlighted enrichment of terms belonging
to the G-protein-coupled-receptor signaling pathway -
with 9 molecules regulated in our dataset (ADRB3, AVPR2
and GRM2, upregulated 2-fold in SCC25 overexpressing
miR-10b; and CNR1 (16-fold), DRD3 (4-fold), HCAR2
(2-fold) and OPRK1 (14-fold), downregulated in these
cells). A recent review addresses mechanisms by which G-
protein-coupled-receptors participate in the regulation of
cell cycle [55] and, in the context of HNSCC, G-protein-
coupled-receptors have been associated with EGFR signal-
ing and cell survival [56].
A significant regulatory network built with deregulated
genes upon overexpression of miR-10b in FaDu includes
genes involved in the regulation of cell cycle progression
and arrest (Figure 8). Although none of these genes have
been implicated in HNSCC or heavily studied in the
context of cancer, it is noteworthy the fact that they re-
late to cell cycle regulation through key players in
HNSCC: TP53, NOTCH1, MYC and HRAS [57].
From this analysis it became clear that the effect of the
overexpression of miR-10b in SCC25 and FaDu, and
miR-196a in keratinocytes do not act upon a large num-
ber of cellular processes but may rather target a small
set of genes, some of which directly or indirectly in-
volved in the progression of cell cycle.
Conclusions
Data on miRNA effects in tumorigenesis and cancer
progression is still controversial and should vary with
cell and cancer types. While individual miRNAs might
possess numerous and distinct targets, they should be
able to contribute to the same tumorigenic processes
through complex, and still mostly unknown, networks.
In HNSCC little is known about the contribution of
miRNA to tumor development and progression, with
several studies lacking corroboration. Besides presenting
data matching to current knowledge, in this study we
show that two miRNAs, miR-196a and miR-10b, play
distinct roles in the regulation of cell proliferation within
a HNSCC background.
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